Navigation Links
Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress
Date:4/8/2013

RIDGEFIELD, Conn., April 8, 2013 /PRNewswire/ -- Boehringer Ingelheim today announced that data from its pivotal STARTVerso™ 1 Phase 3 hepatitis C clinical trial have been accepted for oral presentation as a late-breaker at the International Liver Congress™ 2013: 48th Annual Meeting of the European Association for the Study of the Liver (EASL), taking place from April 24-28 in Amsterdam, The Netherlands.

The STARTVerso™ 1 trial evaluated faldaprevir (BI 201335), an investigational oral protease inhibitor specifically designed to target and inhibit viral replication in the liver, in combination with pegylated interferon and ribavirin (PegIFN/RBV). The study was conducted in treatment-naïve patients with genotype-1 infection, the most common and one of the most challenging types of hepatitis C to cure.

Further sub-analyses from Boehringer Ingelheim's interferon-free Phase 2b SOUND-C2 study will also be presented at the Congress. The SOUND-C2 trial evaluated the interferon-free combination of faldaprevir and BI 207127, an investigational non-nucleoside NS5B polymerase inhibitor, plus ribavirin.

Boehringer Ingelheim is developing faldaprevir as a core component of both interferon-based and interferon-free hepatitis C treatment regimens. Through robust science, Boehringer Ingelheim's goal is to find answers to the ongoing challenges faced by a diverse population of patients with hepatitis C.

The STARTVerso™ 1 abstract can be accessed through the Congress website beginning on April 23 and the SOUND-C2 abstracts can be accessed today. Oral PresentationStudyLead AuthorPresentation DetailsSTARTVerso™ 1

P. Ferenci

Embargoed until April 23 at 12:00PM CET (6:00AM ET)Poster Presentations'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
2. Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
3. Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir
4. Boehringer Ingelheim Cares Foundation Launches Online Giving Report
5. Boehringer Ingelheim Presents Efficacy Data for Tiotropium in Symptomatic Asthma Patients in Relation to Allergic Status
6. Pharmaceutical Leader Boehringer Ingelheim Selects Republica as Cross-Cultural Marketing Agency
7. Boehringer Ingelheim Selects ChemAxon to Power Next-Generation Global Cheminformatics Platform
8. FDA Advisory Committee Recommends Approval for Boehringer Ingelheims Olodaterol for Maintenance Treatment of COPD
9. Boehringer Ingelheim and Ashoka Changemakers Launch Competition to Find Business Models that Transform Health Systems
10. Boehringer Ingelheim Enrolls First Patients in Pivotal Phase 3 Interferon-Free Hepatitis C Trial Program
11. Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014  CytRx Corporation (Nasdaq: ... specializing in oncology, today announced that David J. ... BioCentury,s 2014 NewsMakers in the Biotech Industry Conference on Friday, ... The conference will take place at the Millennium Broadway ... A live and archived webcast of the ...
(Date:9/19/2014)... -- Reductions in kidney failure obtained during ... with diabetes type 2 "Intensive treatment is ... kidneys." Australian researchers have discovered that intensive ... to persistent reductions in kidney failure many years after ... has found that, five and a half years after ...
(Date:9/18/2014)... September 19, 2014 ... http://www.researchandmarkets.com/research/qqjrnh/global_molecular ) has announced the addition of ... report to their offering. ... the study of chromosomes using molecular biology ... genes and chromosomes. It plays a crucial ...
Breaking Medicine Technology:CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 3Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 2Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 3
... /PRNewswire-Asia-FirstCall/ -- China Botanic Pharmaceutical Inc. (NYSE AMEX: ... "Company"), a developer, manufacturer and distributor of botanical ... China, today announced that the Company,s Badger Oil, ... Pharmaceutical Co., Ltd ("Renhuang"), has achieved sales of ...
... Alison MacNeil issued the following statements today regarding ... PBS this week: "When I vaccinated ... are not required to test the safety of vaccines ... thousands of parents with Autistic children report that, like ...
Cached Medicine Technology:China Botanic Pharmaceutical Provides Update on Badger Oil Sales 2China Botanic Pharmaceutical Provides Update on Badger Oil Sales 3Daughter of Journalist Robert MacNeil States that Son Regressed Into Autism After Vaccines 2
(Date:9/19/2014)... Red Bank, NJ (PRWEB) September 19, 2014 ... Jersey’s largest not-for-profit provider of home health care, hospice ... join Deutsche Bank to ring the Opening Bell yesterday ... 1912 by a New Jersey philanthropist and social entrepreneur ... other diseases, VNA Health Group has always worked to ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Boston Scientific ... mesh lawsuit ( http://www.transvaginalmeshlawsuithelp.com/ ) that is scheduled ... month, Bernstein Liebhard LLP reports. According to ... Court, the company asserts that claims involving its Solyx ... Practice and Remedies Code, a section of which shields ...
(Date:9/19/2014)... Sept. 19, 2014 (HealthDay News) -- Your brain structure could ... a new study suggests. Researchers at Yale University found ... known as the parietal cortex may be more likely to ... this area. , , The study, funded by the U.S. ... men and women living in the Northeast. The researchers sought ...
(Date:9/19/2014)... News) -- Although there is mounting evidence that ... and older adults in the United States don,t ... new research. Less than one-quarter of adults ... the Department of Health and Human Services, the ... promoting health and fitness and staying independent, researchers ...
(Date:9/19/2014)... HealthDay Reporter THURSDAY, ... by stress and family conflicts before surgery may face ... new study suggests. Investigators found that patients with ... three times greater risk for complications compared to those ... "We,ve long known that patient quality of life is ...
Breaking Medicine News(10 mins):Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 3Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 4Health News:Brain Structure Might Help Predict Risky Behavior 2Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 3
... WASHINGTON, June 3 AGA Medical Corporation,(AGA), a ... a $2,million criminal penalty in connection with corrupt ... Foreign Corrupt Practices Act,(FCPA), Acting Assistant Attorney General ... a deferred prosecution agreement with AGA,and filed a ...
... issued under second round of Critical Challenges in,Parkinson,s ... The Michael J. Fox,Foundation for Parkinson,s Research is ... non-invasive imaging technologies that would allow,scientists to visualize ... living brain. Such techniques hold potential to,serve as ...
... Million; 57% Increase ... - Record Fourth Quarter U.S. Sales of $2.1 Million; 198% Increase ... Year-Over-Year - ... to be Held Today at 3:30 pm Central Time -, MINNEAPOLIS, June 3 Uroplasty, Inc. ...
... Statistical survey indicates doctors need to be more clear ... News) -- For reasons not easily understood, many patients ... will live longer than their doctors tell them they ... Duke University began telling people being treated for heart ...
... No weight gain seen among those who drink 100% juice, ... 3 (HealthDay News) -- Children who drink 100 percent fruit ... enjoy more nutritious diets than kids who don,t drink the ... was not excessive among children," said lead researcher Theresa A. ...
... the University of Minnesota and University of Minnesota Children,s ... for a young boy,s fatal genetic skin disease, recessive ... and bone marrow transplant. Nate Liao, a 25-month-old from ... , "We have established a new standard of ...
Cached Medicine News:Health News:AGA Medical Corporation Agrees to Pay $2 Million Penalty and Enter Deferred Prosecution Agreement for FCPA Violations 2Health News:Michael J. Fox Foundation for Parkinson's Research Commits up to $2 million to Visualize Alpha-Synuclein Protein in the Brain 2Health News:Michael J. Fox Foundation for Parkinson's Research Commits up to $2 million to Visualize Alpha-Synuclein Protein in the Brain 3Health News:Uroplasty Reports Record Growth for the Fourth Quarter and Fiscal Year 2008 2Health News:Uroplasty Reports Record Growth for the Fourth Quarter and Fiscal Year 2008 3Health News:Uroplasty Reports Record Growth for the Fourth Quarter and Fiscal Year 2008 4Health News:Uroplasty Reports Record Growth for the Fourth Quarter and Fiscal Year 2008 5Health News:Uroplasty Reports Record Growth for the Fourth Quarter and Fiscal Year 2008 6Health News:Uroplasty Reports Record Growth for the Fourth Quarter and Fiscal Year 2008 7Health News:Uroplasty Reports Record Growth for the Fourth Quarter and Fiscal Year 2008 8Health News:Uroplasty Reports Record Growth for the Fourth Quarter and Fiscal Year 2008 9Health News:Uroplasty Reports Record Growth for the Fourth Quarter and Fiscal Year 2008 10Health News:Uroplasty Reports Record Growth for the Fourth Quarter and Fiscal Year 2008 11Health News:Uroplasty Reports Record Growth for the Fourth Quarter and Fiscal Year 2008 12Health News:Heart Failure Patients Overestimate Their Life Expectancy 2Health News:Heart Failure Patients Overestimate Their Life Expectancy 3Health News:Fruit Juice May Be Healthy for Kids: Study 2Health News:Fruit Juice May Be Healthy for Kids: Study 3Health News:U of M sets course for cure of fatal childhood skin disease 2
Our 3.5v Streak or Spot Retinoscope Sets feature instruments with the brightest light output in the industry, reliable handles, and convenient cases....
Our 3.5v Streak or Spot Retinoscope Sets feature instruments with the brightest light output in the industry, reliable handles, and convenient cases....
... Indirect Ophthalmoscope Power Source provides power to ... ophthalmic instruments. The versatile wall/desk power source ... or on the side of a desk ... portable power pack provides power no matter ...
The Welch Allyn 125 BIO is designed to achieve precise binocular viewing and stereopsis easier than ever before. Its observation paths can be adjusted from 48 mm to 74 mm to handle the widest and nar...
Medicine Products: